{"id":"W2773969925","doi":"10.1016/s2213-8587(17)30412-6","title":"Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis","year":2017,"lang":"en","type":"review","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":592,"is_retracted":false,"has_abstract":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"AstraZeneca; National Heart, Lung, and Blood Institute; Amylin Pharmaceuticals","keywords":"Medicine; Semaglutide; Liraglutide; Lixisenatide; Exenatide; Glucagon-like peptide 1 receptor; Internal medicine; Type 2 diabetes; Placebo; Myocardial infarction; Dulaglutide; Meta-analysis; Adverse effect; Odds ratio; Stroke (engine); Hazard ratio; Diabetes mellitus; Agonist; Endocrinology; Receptor; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004997244,0.00266107,0.01250353,0.001589618,0.0003568599,0.002063551,0.001585068,0.001756721,0.003298606],"category_scores_gemma":[0.008016119,0.001451134,0.03062875,0.00257355,0.0003799438,0.001268518,0.001169414,0.002703149,0.0003863649],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009195121,"about_ca_system_score_gemma":0.0009226148,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003731364,"about_ca_topic_score_gemma":0.008966545,"domain_scores_codex":[0.9968672,0.001424398,0.0007169411,0.0005117626,0.0002782448,0.0002014019],"domain_scores_gemma":[0.9960231,0.002841531,0.000556007,0.0002493728,0.0002315915,0.00009843766],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.007028993,0.00004663788,0.006820671,0.0590408,0.9123622,0.0001314892,0.0000393032,0.0005205674,0.0003082821,0.0001012,0.0008995119,0.01270034],"study_design_scores_gemma":[0.001400009,0.0002332972,0.005623338,0.002157883,0.9889014,0.00006592875,0.00003045116,0.00017053,0.00007586031,0.00019833,0.001117127,0.00002598535],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01454126,0.9832358,0.0007443308,0.0002002473,0.0003657359,0.00006534799,0.0004855641,0.00004219755,0.000319514],"genre_scores_gemma":[0.3884842,0.6041635,0.002516223,0.001759576,0.0008411799,0.0002746868,0.001209858,0.0000593038,0.0006913922],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.01250353,"threshold_uncertainty_score":0.02642822,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09996280311863774,"score_gpt":0.3291057581735825,"score_spread":0.2291429550549447,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}